Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Null Results in Brief

Aspirin Does Not Prevent Pancreatic Cancer in a Large Asian Cohort

Min-Hyung Kim, Sang Min Park, Young Ho Yun and In Cheol Hwang
Min-Hyung Kim
1Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
2Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Min-Hyung Kim
Sang Min Park
1Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
2Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Young Ho Yun
1Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, South Korea.
2Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
In Cheol Hwang
2Department of Family Medicine, Gil Medical Center, Gachon University College of Medicine, Incheon, South Korea.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for In Cheol Hwang
  • For correspondence: spfe0211@gmail.com
DOI: 10.1158/1055-9965.EPI-18-1325 Published April 2019
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Evidence has suggested that aspirin reduces the incidence of several cancers, but these benefits may not occur with pancreatic cancer.

Methods: A 12-year nationwide longitudinal cohort merged with the health checkup data was divided into “exposure ascertainment period” and “outcome ascertainment period” to avoid immortal time bias. The daily defined dose system was used to indicate the drug exposure.

Results: We found no significant association between aspirin use and incident pancreatic cancer based on HR.

Conclusions: Aspirin does not prevent pancreatic cancer.

Impact: A large Asian cohort study with reliable medication information affirms no impact of aspirin on pancreatic cancer development.

Introduction

As pancreatic cancer is usually advanced and unresectable at diagnosis, early detection and chemoprevention are important (1). Aspirin plays a critical role in preventing vascular disease and has been suggested as a potential cancer-preventive agent. Mechanistically, aspirin may reduce cancer risk via cyclooxygenase-2 inhibition or other proapoptotic effects (2). Epidemiologic studies have suggested that daily aspirin reduces the incidence of colorectal and several other cancers, but these benefits may not occur with pancreatic cancer (3).

Two case–control studies reported that aspirin lowered the risk of pancreatic cancer (4, 5), whereas the Queensland Pancreatic Cancer Study found no benefit (6). However, aspirin usage in these studies was ascertained by self-report, a critical flaw that may have. More recently, a prospective analysis of two large U.S. cohorts determined plasma levels of aspirin metabolites (salicylate levels) and found no association between regular aspirin use and future risk of pancreatic cancer (7).

South Korea has a single-payer health insurance system, the National Health Insurance Services (NHIS), which covers almost the entire population. NHIS also provides health examinations biennially to all individuals ≥40 years old. Prescription data (medication identifier, dosage, and duration) from the NHIS claims database allow accurate determination of the medication exposure. We used this database to evaluate the influence of aspirin on pancreatic cancer risk. We hypothesized that regular aspirin use would reduce the risk of incident pancreatic cancer.

Materials and Methods

The institutional review board of Seoul National University Hospital (Seoul, South Korea) approved the protocol (IRB number: E-1509-004-699). Detailed methodology information was reported previously (8).

We obtained NHIS data from a standardized 12-year longitudinal cohort (the Health Examination Cohort) consisting of individuals who underwent ≥1 biennial examination between January 1, 2002, and December 31, 2003. Data from the first 5 years (January 1, 2002, to December 31, 2006) was used to identify cohort inclusion and exclusion criteria, as well as the exposures and potential confounding factors related to aspirin use and pancreatic cancer. January 1, 2007, was designated the cohort entry date. The follow-up observation period extended through December 31, 2013, to identify newly diagnosed pancreatic cancer cases while avoiding immortal time bias. We excluded the participants diagnosed with any cancer [indicated by International Classification of Diseases code–10th Revision (ICD-10) “C” codes] before December 31, 2006. We included 461,489 participants in our analysis.

Sociodemographic, medical history, cumulative prescription, and health-related habits data during the first 5 years (before cohort entry date) were extracted. Pancreatic cancer cases were defined as individuals who visited the hospital at least once with a C25 ICD-10 code and met any of these criteria during follow-up: three outpatient visits related to the code, admission for ≥3 days with the code diagnosis, receipt of any curative cancer treatments for the Korean Diagnosis-Related Group code “G60-Digestive Malignancy,” or death from a cause related to the code. To determine drug exposure, we used the daily defined dose (DDD) system of the World Health Organization Collaborating Center for Drug Statistics Methodology.

Results

Table 1 shows the characteristics of pancreatic cancer cases and controls. In this cohort study with reliable medication information, we found no significant association between aspirin use and incident pancreatic cancer based on HRs (Table 2). The lack of association persisted when we evaluated subgroups stratified by available variables. This contrasts with a previously reported association between aspirin use and reduced pancreatic cancer incidence in diabetic patients (7).

View this table:
  • View inline
  • View popup
Table 1.

Comparison of basic characteristics between pancreatic cancer cases and controls

View this table:
  • View inline
  • View popup
Table 2.

Factors associated with incident pancreatic cancer

Discussion

Besides avoiding obesity and smoking, few options exist for preventing pancreatic cancer. Although aspirin is appealing for chemoprevention, none of the possible mechanisms has been convincingly established (4), and epidemiologic studies yielded mixed results. The highest-quality previous study was that of Khalaf and colleagues, with its large size, long follow-up, prospective design, and objective ascertainment of aspirin usage (7). However, all participants were health care workers, limiting their ability to represent the general population, and plasma salicylate levels do not definitively confirm aspirin exposure.

As aspirin's cardiovascular protective effects are well established, only individuals without cardiovascular risks may be ethically eligible for long-term clinical trials. To generate unbiased results regarding aspirin chemoprevention of cancer, well-designed cohort studies could be the best alternative.

Our results add to current evidence that aspirin does not prevent incident pancreatic cancer. Although our study is based on observational data, it was designed to estimate the effect size of drug exposure while minimizing bias. We used a randomly selected sample to minimize selection bias, determined aspirin exposure using national prescription database and validated DDD system to minimize recall bias, and choose a study time window to minimize survivor bias and immortal time bias.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors' Contributions

Conception and design: M.-H. Kim, S.M. Park, Y.H. Yun, I.C. Hwang

Development of methodology: M.-H. Kim, S.M. Park, I.C. Hwang

Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): S.M. Park, I.C. Hwang

Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): M.-H. Kim, S.M. Park, I.C. Hwang

Writing, review, and/or revision of the manuscript: M.-H. Kim, S.M. Park, Y.H. Yun, I.C. Hwang

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): M.-H. Kim, S.M. Park

Study supervision: M.-H. Kim, S.M. Park, Y.H. Yun, I.C. Hwang

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

  • Received December 7, 2018.
  • Revision received January 7, 2019.
  • Accepted January 10, 2019.
  • Published first January 14, 2019.
  • ©2019 American Association for Cancer Research.

References

  1. 1.↵
    1. Chari ST,
    2. Kelly K,
    3. Hollingsworth MA,
    4. Thayer SP,
    5. Ahlquist DA,
    6. Andersen DK,
    7. et al.
    Early detection of sporadic pancreatic cancer: summative review. Pancreas 2015;44:693–712.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Elwood PC,
    2. Gallagher AM,
    3. Duthie GG,
    4. Mur LA,
    5. Morgan G
    . Aspirin, salicylates, and cancer. Lancet 2009;373:1301–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Algra AM,
    2. Rothwell PM
    . Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518–27.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Streicher SA,
    2. Yu H,
    3. Lu L,
    4. Kidd MS,
    5. Risch HA
    . Case-control study of aspirin use and risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2014;23:1254–63.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    1. Risch HA,
    2. Lu L,
    3. Streicher SA,
    4. Wang J,
    5. Zhang W,
    6. Ni Q,
    7. et al.
    Aspirin use and reduced risk of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2017;26:68–74.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Kho PF,
    2. Fawcett J,
    3. Fritschi L,
    4. Risch H,
    5. Webb PM,
    6. Whiteman DC,
    7. et al.
    Nonsteroidal anti-inflammatory drugs, statins, and pancreatic cancer risk: a population-based case-control study. Cancer Causes Control 2016;27:1457–64.
    OpenUrl
  7. 7.↵
    1. Khalaf N,
    2. Yuan C,
    3. Hamada T,
    4. Cao Y,
    5. Babic A,
    6. Morales-Oyarvide V,
    7. et al.
    Regular use of aspirin or non-aspirin nonsteroidal anti-inflammatory drugs is not associated with risk of incident pancreatic cancer in two large cohort studies. Gastroenterol 2018;154:1380–90.
    OpenUrl
  8. 8.↵
    1. Kim MH,
    2. Chang J,
    3. Kim WJ,
    4. Banerjee S,
    5. Park SM
    . Cumulative dose threshold for the chemopreventive effect of aspirin against gastric cancer. Am J Gastroenterol 2018;113:845–54.
    OpenUrl
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 28 (4)
April 2019
Volume 28, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Aspirin Does Not Prevent Pancreatic Cancer in a Large Asian Cohort
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Aspirin Does Not Prevent Pancreatic Cancer in a Large Asian Cohort
Min-Hyung Kim, Sang Min Park, Young Ho Yun and In Cheol Hwang
Cancer Epidemiol Biomarkers Prev April 1 2019 (28) (4) 826-828; DOI: 10.1158/1055-9965.EPI-18-1325

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Aspirin Does Not Prevent Pancreatic Cancer in a Large Asian Cohort
Min-Hyung Kim, Sang Min Park, Young Ho Yun and In Cheol Hwang
Cancer Epidemiol Biomarkers Prev April 1 2019 (28) (4) 826-828; DOI: 10.1158/1055-9965.EPI-18-1325
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Associations of ACEi and ARB with CRC risk
  • PDE5 Inhibitor Use and Precursors of Colorectal Cancer
  • Association Between Serum Iron Biomarkers and Breast Cancer
Show more Null Results in Brief
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement